#Paris #France #Lung Cancer #Coreline Soft #IMPULSION

Coreline Soft and the IMPULSION Project

On November 11, 2025, Coreline Soft, a prominent figure in AI-driven chest diagnostic solutions, announced its designation as the exclusive artificial intelligence supplier for the IMPULSION initiative in France. This project, designed to enhance lung cancer screening, is spearheaded by AP-HP (Assistance Publique–Hôpitaux de Paris) and is significantly funded by INCa (Institut National du Cancer).

IMPULSION refers to the national efforts aimed at implementing a systematic lung cancer screening program utilizing advanced imaging methods. With a budget of €6 million, this initiative is set to impact more than 100 medical centers across the country. This ambitious project intends to not only address early detection but also improve the quality of care provided to patients throughout France.

The project is co-led by esteemed medical professionals including Professor Marie-Pierre Revel from AP-HP and Professor Sébastien Couraud from HCL (Hospices Civils de Lyon). Their collaboration underscores a commitment to make significant strides in lung cancer management through early detection efforts, which are crucial for improving patient outcomes.

As part of this initiative, Coreline Soft will deploy a nationwide supply system utilizing local cloud infrastructure to facilitate AI adoption across participating hospitals. These advancements will enhance diagnostic capabilities, specifically in lung cancer screening and ultimately in nodule management. The collaboration with the French Society of Radiology (SFR) will allow Coreline Soft to provide extensive training for physicians involved in the project, ensuring that medical staff are well-equipped to utilize the latest AI-based tools effectively.

The training programs will include hands-on sessions focusing on lung cancer screening techniques and utilizing advanced AI detection capabilities to aid clinical practice. Enhancing healthcare professionals' expertise is vital, as it directly impacts patient care quality.

Coreline Soft's recent progress in Europe is evident, especially following the acquisition of the CE MDR Class IIb certification in 2024. The firm has successfully contributed to national lung cancer screening schemes in several European nations, including Germany and Italy, gaining strong references and demonstrating clinical efficacy. Such international experience has fortified Coreline's reputation, enabling it to adapt and implement its solutions effectively across various healthcare systems.

Furthermore, beyond Europe, Coreline Soft has developed a robust commercial presence in North America. They have established beneficial partnerships with reputable institutions, such as Temple Health and Baylor College of Medicine, reinforcing its position as a leading provider of AI-powered medical imaging solutions.

Coreline Soft remains dedicated to improving the early detection of lung cancer and optimizing clinical workflows for managing thoracic diseases. They are at the forefront of innovating medical imaging techniques and enhancing population health management strategies, ensuring greater accessibility and quality of care for lung cancer patients during the pilot study and beyond.

As the IMPULSION initiative unfolds, it shows promise for a lasting impact on lung cancer screening approaches not only within France but potentially serving as a reference model for global healthcare strategies in lung cancer management. Through strategic partnerships and innovative technology, Coreline Soft is poised to play a pivotal role in shaping the future of lung cancer diagnosis and treatment.